INTRODUCTION {#s1}
============

Coronary artery disease (CAD), also named as coronary heart disease (CHD) or ischaemic heart disease (IHD), has become one of the most common cause of morbidity and mortality in cardiovascular diseases (CVDs) all around the world, especially in the industrial countries \[[@R1]\]. Coronary heart disease (CHD) is caused by obstruction of epicardial coronary artery that supplies blood and oxygen to the heart. Multiple factors, such as lifestyle and environmental factors, play critical roles in the occurrence and progression of CHD. The characteristic pathological changes of CAD is atherosclerosis that results from the endothelial injury or functional disorder, which is triggered by the abnormal accumulation of lipoproteins in the intima \[[@R2]\]. Plenty of cells such as T cells, dendritic cells, neutrophils and macrophages are also involved into the process of the disease. Traditional environmental risk factor for CAD contains tobacco smoking, hypertension, diabetes or hyperglycemia, hyperlipidemia especially high levels of LDL and obesity or overweight \[[@R3]\]. There is a growing worldwide awareness of that heritable factors play an important role in the progress of atherosclerosis \[[@R4]\] and relatively a great many genome-wide association studies (GWAS) have confirmed the effect of genes in CAD \[[@R5]--[@R7]\].

Atherosclerosis is actually a chronic inflammatory reaction in blood vessels and includes two remarkable steps, foam cell formation and smooth muscle cell recruitment. Chemokine (C-X-C motif) ligand 12 (CXCL12), also called stromal cell-derived factor-1 (SDF-1), is one of the members of CXC chemokine family \[[@R8]\] and mostly known for its crucial role in the accumulation of smooth muscle progenitor cells (SPCs) \[[@R9]\]. It will trigger MAPK and PI3K signal pathway \[[@R10]\] by binding to a G protein-coupled receptor, CXCR4, and contribute to macrophage migration which results from lipid accumulation especially low-density lipoprotein (LDL) \[[@R11]\]. Additionally, it is identified that different single nucleotide polymorphisms (SNPs) of *CXCL12* participates in various disease such as neck and head squamous cell carcinoma \[[@R12]\], myelodysplastic syndromes \[[@R13]\], multiple sclerosis \[[@R14]\], etc. Here, we choose six SNPs (rs1065297, rs1801157, rs266089, rs197452, rs2839693 and rs10793538) of *CXCL12* to explore which SNPs are associated with the risk of CAD.

RESULTS {#s2}
=======

After all the experiments and data compilation, 597 cases (376 males and 221 females) and 685 controls (385 males and 300 females) were included in the final analysis. As listed in Table [1](#T1){ref-type="table"}, the mean age of cases is 61.44 while the control group is 48.59. The p value of age and sex were less than 0.001 and 0.014, respectively. Clinical and biochemical index of information in CAD patients in the Table [1](#T1){ref-type="table"}, including ALT, AST, GGT, TP, GLU, TG, TC, HDL, LDL, apoA, apoB, LP(a), ect.

###### Basic information of case and control groups

                   Case          Control   *p*                 
  ---------------- ------------- --------- ------------- ----- --
  \<55             41            124       214           184   
  ≥55              180           252       86            101   
  total            597           685       0.014               
  Mean age         61.44         48.59     *p* \<0.001         
  ALT (U/L)        31.15±2.11                                  
  AST (U/L)        36.41±2.93                                  
  GGT (U/L)        44.65±3.77                                  
  TP(g/L)          66.39±0.3                                   
  GLU (mmol/L)     6.34±0.11                                   
  TG (mmol/L)      1.8±0.07                                    
  TC (mmol/L)      4.09±0.06                                   
  HDL-C (mmol/L)   1.13±0.01                                   
  LDL-C (mmol/L)   1.92±0.04                                   
  APOA1 (g/L)      1.26±0.01                                   
  APOB (g/L)       1±0.02                                      
  Lp(a) (mg/L)     239.2±12.14                                 

ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma-glutamyl transpeptidase, TP: total protein, GLU: glucose, TG: triglyceride, TC: total cholesterol, HDL: high-density lipoprotein, LDL: low-density lipoprotein, apoA: apolipoprotein A, apoB: apolipoprotein B, LP(a): lipoprotein.

*p* \<0.05, statistical significance.

The basic characteristics of the study subjects stratified by different genotype are shown in Table [2](#T2){ref-type="table"}. We found significant differences in apoB concentrations with rs1065297 and rs10793538 different genotype. For rs1065297, the mean serum apoB concentration was 1.03 for the GG genotype (highest), 0.76 for the GA genotype (lowest), 1.01 for AA genotype (*p* = 0.003). For rs10793538, the mean serum apoB concentration of TT, TA and AA is 1.03, 0.76, and 1.01 respectively.

###### Characteristics of the subjects with 3 different genotypes

  SNP                        Genotype     p                         
  ------------ ------------- ------------ ------------ ------------ -------
  rs1065297                  GG           GA           AA           
  LDL-C        sample size   1            27           402          
               Mean±std      2.43         1.53±0.65    1.94±0.84    0.036
  apoB         sample size   1            27           401          
               Mean±std      1.03         0.76±0.31    1.01±0.37    0.003
  rs1801157                  CC           CT           TT           
  TP           sample size   272          148          22           
               Mean±std      67.03±6.33   65.44±6.26   64.83±6.47   0.023
  rs10793538                 TT           TA           AA           
  apoB         sample size   1            26           402          
               Mean±std      1.03         0.76±032     1.01±0.37    0.004

*p* \<0.05, statistical significance.

The allele information including MAF, HWE, OR etc. were demonstrated in Table [3](#T3){ref-type="table"}. In the allele model, rs1065297, rs266089 and rs10793538 in *CXCL12* gene associated with the risk of CAD. Among them *CXCL12* rs1065297 and rs10793538 decreased CAD risk (rs1065297: OR=0.64, 95%CI: 0.46-0.90, *p*=0.010; rs10793538: OR=0.67, 95%CI: 0.47-0.93, *p*=0.016). Rs266089 in *CXCL12* gene increased the risk of CAD (OR=1.23, 95%CI: 1.00-1.51, *p*=0.046). Stratified according to gender, in the allele model, rs266089 and rs2839693 in *CXCL12* gene were associated with the risk of CAD in men, while rs1065297 and rs10793538 in *CXCL12* gene were associated with the risk of CAD in women.

###### Basic SNPs in *CXCL12* gene summary of all study participants

  SNP          Base/Change   MAF     HWE*p*   Total   Male               Female                                               
  ------------ ------------- ------- -------- ------- ------------------ -------- ----------------- ------- ----------------- -------
  rs1065297    G/A           0.046   0.07     0.04    0.64(0.46-0.90)    0.01     0.74(0.48-1.14)   0.166   0.51(0.29-0.89)   0.017
  rs1801157    T/C           0.217   0.21     0.644   1.04(0.86-1.26)    0.655    1(0.78-1.27)      0.999   1.1(0.81-1.49)    0.54
  rs266089     A/G           0.19    0.16     0.201   1.23(1.00-1.51)    0.046    1.46(1.11-1.91)   0.006   0.99(0.72-1.36)   0.938
  rs197452     T/C           0.116   0.116    0.852   1.00(0.78-1.27)    0.97     0.96(0.7-1.31)    0.781   1.05(0.72-1.53)   0.808
  rs2839693    T/C           0.168   0.145    0.642   1.19(0.96-1.47)    0.113    1.44(1.09-1.89)   0.01    0.89(0.63-1.26)   0.529
  rs10793538   T/A           0.046   0.068    0.119   0.669(0.47-0.93)   0.016    0.77(0.5-1.2)     0.249   0.52(0.3-0.92)    0.019

*p* \<0.01, statistical significance for HWE

*p* \<0.05, statistical significance.

We further explored the relationship between *CXCL12* gene and CAD in four genetic models (genotype, dominant, recessive and log-additive model) by unconditional logistic regression (Table [4](#T4){ref-type="table"}). Results show that the odds of having CAD would be 1.30-fold (95%CI: 1.30-1.65, *p*=0.028) with GA-AA genotype, compared with the subjects with the homozygous GG genotype in the dominant model. A log-additive model revealed a potential association with CAD (OR = 0.67, 95%CI: 0.48-0.94, *p*= 0.018). But after adjusting by gender and age, we found no association between the SNPs and CAD.

###### Associations between *CXCL12* SNPs and CAD

  SNP          Model          Genotype   control       case          Crude analysis     adjusted by age and gender                     
  ------------ -------------- ---------- ------------- ------------- ------------------ ---------------------------- ----------------- ------
  rs266089     Codominant     G/G        487 (71.2%)   391 (65.5%)   1                  0.086                        1                 0.18
                              G/A        175 (25.6%)   185 (31%)     1.32 (1.03-1.68)                                1.31(0.97-1.75)   
                              A/A        22 (3.2%)     21 (3.5%)     1.19 (0.64-2.19)                                0.91(0.43-1.94)   
               Dominant       G/G        487 (71.2%)   391 (65.5%)   1                  **0.028**                    1                 0.11
                              G/A-A/A    197 (28.8%)   206 (34.5%)   1.30 (1.03-1.65)                                1.26(0.95-1.67)   
               Recessive      G/G-G/A    662 (96.8%)   576 (96.5%)   1                  0.77                         1                 0.65
                              A/A        22 (3.2%)     21 (3.5%)     1.10 (0.60-2.02)                                0.84(0.40-1.78)   
               Log-additive   \-\--      \-\--         \-\--         1.23 (1.00-1.50)   0.048                        1.17(0.91-1.49)   0.22
  rs10793538   Codominant     A/A        594 (87.2%)   544 (91.1%)   1                  0.06                         1                 0.61
                              T/A        81 (11.9%)    51 (8.5%)     0.69 (0.48-0.99)                                0.91(0.58-1.41)   
                              T/T        6 (0.9%)      2 (0.3%)      0.36 (0.07-1.81)                                0.40(0.05-3.21)   
               Dominant       A/A        594 (87.2%)   544 (91.1%)   1                  **0.025**                    1                 0.54
                              T/A-T/T    87 (12.8%)    53 (8.9%)     0.67 (0.46-0.95)                                0.87(0.57-1.35)   
               Recessive      A/A-T/A    675 (99.1%)   595 (99.7%)   1                  0.2                          1                 0.37
                              T/T        6 (0.9%)      2 (0.3%)      0.38 (0.08-1.88)                                0.40(0.05-3.25)   
               Log-additive   \-\--      \-\--         \-\--         0.67 (0.48-0.94)   **0.018**                    0.86(0.57-1.28)   0.45

*p* \<0.05, statistical significance.

Stratified according to gender, we found that under the dominant model rs266089 "GA-AA" genotype and rs2839693 "CT-TT" genotype increased the risk of CAD in men (rs266089: OR=1.54, 95%CI: 1.13-2.10, *p*=0.006; rs2839693: OR=1.51, 95%CI: 1.10-2.07, *p*=0.010) (Table [5](#T5){ref-type="table"}). While in the women, rs1065297 and rs10793538 decreased the CAD risk under the log-additive model (rs1065297: OR=0.52, 95%CI: 0.30-0.91, *p*=0.021; rs10793538: OR=0.53, 95%CI: 0.31-0.93, *p*=0.027) (Table [5](#T5){ref-type="table"}).

###### The relationship between *CXCL12* genetic polymorphism and CAD was analyzed according to the gender stratification

           SNP          Model          Genotype    control     case        Crude analysis     adjusted by age and gender                     
  -------- ------------ -------------- ----------- ----------- ----------- ------------------ ---------------------------- ----------------- -------
  Male     rs266089     Genotype       GG          284         242         1                  0.022                        1                 0.054
                                       GA          92          119         1.52(1.10-2.10)    0.011                        1.57(1.09-2.28)   0.017
                                       AA          10          18          1.76(0.78-3.99)    0.176                        1.34(0.51-3.50)   0.551
                        Dominant       GG          284         242         1                  0.006                        1                 0.016
                                       GA-AA       102         137         1.54(1.13-2.10)                                 1.55(1.08-2.21)   
                        Recessive      GG-GA       376         361         1                  0.282                        1                 0.733
                                       AA          10          18          1.56(0.69-3.52)                                 1.18(0.45-3.07)   
                        Log-additive   \-\--       \-\--       \-\--       1.45(1.11-1.19)    0.007                        1.41(1.04-1.93)   0.029
           rs2839693    Genotype       CC          292         252         1                  0.036                        1                 0.19
                                       CT          86          111         1.50(1.01-2.08)    0.016                        1.40(0.96-2.04)   
                                       TT          9           13          1.67(0.70-3.98)    0.244                        1.45(0.52-4.08)   0.477
                        Dominant       CC          292         252         1                  0.01                         1                 0.069
                                       CT-TT       95          124         1.51(1.10-2.07)                                 1.40(0.97-2.02)   
                        Recessive      CC-CT       378         363         1                  0.353                        1                 0.584
                                       TT          9           13          1.50(0.64-3.56)                                 1.33(0.48-3.73)   
                        Log-additive   \-\--       \-\--       \-\--       1.42 (1.08-1.87)   0.012                        1.33(0.97-1.83)   0.079
  Female   rs1065297    Genotype       AA          257         203         1                  0.17                         1                 0.614
                                       AG          40          18          0.57(0.32-1.02)    0.06                         0.68(0.32-1.45)   0.323
                                       GG          3           0           /                  /                            /                 /
                        Dominant       AA          257         203         1                  0.032                        1                 0.244
                                       AG-GG       43          18          0.53(0.3-0.95)                                  0.64(0.3-1.35)    
                        Recessive      AA-AG       297         221         1                  /                            1                 /
                                       GG          3           0           /                                               /                 
                        Log-additive   \-\--       \-\--       \-\--       0.52(0.3-0.91)     0.021                        0.63(0.31-1.28)   0.199
           rs10793538   Genotype       AA          258         203         1                  0.206                        1                 0.787
                                       AT          39          18          0.59(0.33-1.06)    0.075                        0.77(0.36-1.63)   0.489
                                       TT          3           0           /                  /                            /                 /
                        Dominant       AA          258         203         1                  0.041                        1                 0.379
                                       AT-TT       42          18          0.54(0.3-0.97)                                  0.72(0.34-1.51)   
                        Recessive      AA-AT       297         221         1                  /                            1                 /
                                       TT          3           0           /                                               /                 
                        Log-additive   **\-\--**   **\-\--**   **\-\--**   0.53(0.31-0.93)    0.027                        0.69(0.34-1.4)    0.307

*p* \<0.05, statistical significance.

Stratified according to age, we found that under the log-additive model, rs197452 decreased the risk of CAD in less than 50 years old group (rs197452: OR=0.63, 95%CI: 0.39-1.00, *p*=0.042). While in more than 50 years old group, we did not find significant results (Table [6](#T6){ref-type="table"}).

###### The relationship between *CXCL12* genetic polymorphism and CAD was analyzed according to the age stratification

         SNP            Model        Genotype      control       case               Crude analysis   adjusted by age and gender           
  ------ -------------- ------------ ------------- ------------- ------------------ ---------------- ---------------------------- ------- -------
  \<55   rs197452       Codominant   C/C           393 (78.9%)   141 (85.5%)        1                0.073                        1       0.081
                        C/T          101 (20.3%)   24 (14.6%)    0.66 (0.41-1.08)                    0.68 (0.42-1.11)                     
                        T/T          4 (0.8%)      0 (0%)        0.00 (0.00-NA)                      0.00 (0.00-NA)                       
         Dominant       C/C          393 (78.9%)   141 (85.5%)   1                  0.06             1                            0.077   
                        C/T-T/T      105 (21.1%)   24 (14.6%)    0.64 (0.39-1.03)                    0.65 (0.40-1.06)                     
         Recessive      C/C-C/T      494 (99.2%)   165 (100%)    1                  0.13             1                            0.11    
                        T/T          4 (0.8%)      0 (0%)        0.00 (0.00-NA)                      0.00 (0.00-NA)                       
         Log-additive   \-\--        \-\--         \-\--         0.63 (0.39-1.00)   **0.042**        0.64 (0.40-1.02)             0.053   
  ≥55    rs197452       Codominant   C/C           141 (75.4%)   328 (75.9%)        1                0.97                         1       0.96
                        C/T          42 (22.5%)    94 (21.8%)    0.96 (0.64-1.46)                    0.95 (0.63-1.44)                     
                        T/T          4 (2.1%)      10 (2.3%)     1.07 (0.33-3.48)                    1.09 (0.33-3.53)                     
         Dominant       C/C          141 (75.4%)   328 (75.9%)   1                  0.89             1                            0.86    
                        C/T-T/T      46 (24.6%)    104 (24.1%)   0.97 (0.65-1.45)                    0.97 (0.65-1.44)                     
         Recessive      C/C-C/T      183 (97.9%)   422 (97.7%)   1                  0.89             1                            0.88    
                        T/T          4 (2.1%)      10 (2.3%)     1.08 (0.34-3.50)                    1.10 (0.34-3.55)                     
         Log-additive   \-\--        \-\--         **\-\--**     0.99 (0.69-1.40)   0.94             0.98 (0.69-1.39)             0.92    

*p* \<0.05, statistical significance.

Only one block was detected in the analysis using haploview software. The block consisted of rs1801157, rs266089, rs197452 and rs2839693 (Figure [1](#F1){ref-type="fig"}). The result of the association between *CXCL12* haplotype and CAD risk were listed in Table [7](#T7){ref-type="table"}. We found that haplotype "TGCC" in the block increased CAD risk (OR=1.26, 95%CI: 1.00-1.58, *p*=0.046) (Table [7](#T7){ref-type="table"}). While there was no statistical valid after adjusting age and sex.
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###### *CXCL12* haplotype frequencies and their association with CAD

  Haplotype   Freq     case    control   OR (95% CI)          *p*-value
  ----------- -------- ------- --------- -------------------- -----------
  CGCC        0.4943   0.476   0.51      1.00                 \-\--
  TGCC        0.2131   0.217   0.21      1.10 (0.90 - 1.35)   0.34
  CACT        0.1532   0.167   0.141     1.26 (1.00 - 1.58)   0.046
  CGTC        0.1158   0.116   0.116     1.06 (0.82 - 1.37)   0.64
  CACC        0.0212   0.024   0.019     1.29 (0.75 - 2.21)   0.36

*p* \<0.05, statistical significance.

DISCUSSION {#s3}
==========

It is widely acknowledged that hereditary factors contribute importantly to the risk of CAD and a large amount of genes and SNPs have been identified to be associated with CAD in various races \[[@R15], [@R16]\]. In the current study, we detected 6 SNPs to identify the relationship between CAD and *CXCL12* and found three (rs1065297, rs266089 and rs10793538) significant SNPs. As far as we known, these 3 SNPs were first reported to be associated with CAD risk.

GWAS reported that *SDF-1* gene (CXCL-12), which located on 10q11.1 and involved in progenitor cell proliferation, traffic, adhesion and regulates cell survival, associated with cardiovascular disease susceptibility. We also found that rs266089 in *CXCL12* gene increased the CAD risk in total population and in men; rs2839693 in *CXCL12* gene associated with the risk of CAD in men. A study explored the *SDF1* SNPs for prognostic impact in patients with cardiovascular disease, found that cardiovascular who were *SDF1* rs2839693 and rs266089 minor allele carriers showed a significantly better event-free survival probability compared to homozygote carriers of major allele \[[@R17]\]. Apart from this, an article reported that homozygous genotype of the minor allele of rs2839693, A/A, was shown to be significantly decreased in ITP patients, which suggested a protective role of these genotypes \[[@R18]\].

Published studies have shown that the relationship between rs1801157 and CAD susceptibility exist inconsistent. Some studies suggested that rs1801157 in *CXCL12* gene is not associated with the risk of coronary heart disease \[[@R19]--[@R21]\]. However, some studies have suggested that *CXCL12* gene may affect the risk of coronary heart disease \[[@R22]--[@R25]\]. By integrating the results of other studies, meta-analysis showed that the rs1801157 in *CXCL12* gene was not associated with the risk of coronary heart disease. In our research, we did not find the relationship between SNP rs1801157 and susceptibility to CAD. But, we found that significant differences in TP concentrations with rs1801157 different genotype.

Actually there were some limitations in our study. The sample volume of the case-control study (597 cases and 685 controls) was not relatively large enough. The most defect of our specimen was the mismatching of age and sex. It would still have some random error although in a certain extent though we indeed did some adjustment. The most useful way to solve the question we thought is to take them as independent factors. The main methods of controlling the confounding factors include restrictions on randomization, matching, stratified analysis, multivariate analysis. Due to the age and sex is not match, in the process of statistical analysis, ORs and 95%CIs were computed based on unconditional logistic regression adjusted by age and gender. In addition to, further stratified analysis by sex and age were performed to eliminate the influence of confounding factors.

Our findings in the case-control study provide new evidence for the relationship between SNPs and haplotype of *CXCL12* with CAD risk. What is more, we found different influence of the SNPs between males and females. It\'s a pity that we did not clarify the mechanism of how the SNPs affect the risk of CAD but we thought it would be a new research direction in the future.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The protocol in this study conformed to the principles of the Declaration of Helsinki and was ratified by the Ethical Committee of the First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, China. Signed informed consent was obtained from each participant.

Study participants {#s4_2}
------------------

A total of 597 patients were recruited in the department of cardiology in First Affiliated Hospital of Xi'an Jiaotong University from. At least two experienced cardiologists performed the diagnosis of CHD according to American Heart Association guidelines \[[@R26]\]. All patients were confirmed by the obstruction of at least 1 large epicardial coronary artery by atheromatous plaque using coronary angiography (\>50% diameter stenosis in at least one of the major coronary arteries). Patients who met the exclusion criteria will be excluded from this study: alcohol abuse, diabetes, a history of smoking, chronic lung disease, xanthelasma, and evidence of noncoronary atherosclerotic disease. We also collected the clinical data of CAD patient, including Serum concentrations of ALT, AST, GGT, TP, GLU, TG, TC, HDL-C, LDL-C, APOA, APOB, Lp(a).

Additionally, there were in total 708 relative healthy controls in other departments were involved but 23 were excluded for the defective information or the poor DNA quality. Eventually, 597 case groups and 685 control groups with informed consent were taken into consideration to explore the association between the 6 SNPs and CAD. All the subjects were Chinese Han people and the information was collected by the medical records.

SNP selection and genotyping {#s4_3}
----------------------------

We selected candidate SNPs of *CXCL12* according to previous published papers which demonstrated association with CAD in other ethnic lines and only MAF\>5% in the Hapmap Asian population were valid \[[@R17]\]. Finally, a number of 6 SNPs were chosen for further analysis. Genomic DNA extracted and concentrated were accomplished using GoldMag-Mini Purification Kit (GoldMag Co. Ltd. Xian city, China) and spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA), respectively. Sequenom MassARRAY RS1000 was applied to genotype the candidate SNPs and subsequently data management and analysis were performed by the Sequenom Typer 4.0 Software \[[@R27]\].

Statistical analysis {#s4_4}
--------------------

For continuous variable, presented as means ± standard deviations (SDs), performed by T-test; for categorical variables performed by Pearson\'s chi-square test. From variance analysis assess the differences in continuous variables among the subjects with three genotypes of related genes.

Hardy-Weinberg equilibrium (HWE) was performed for each SNP in control groups using exact test. The differences in allele and genotype frequencies for each SNP between cases and controls were detected using Pearson Chi-Square (χ^2^) test \[[@R28]\]. ORs and 95%CIs were computed based on unconditional logistic regression \[[@R29]\]. Further stratified analysis by sex and age were performed to eliminate the influence of confounding factors. The four genetic models, dominant, co-dominant, recessive and log-additive were applied by PLINK software (<http://pngu.mgh.harvard.edu/purcell/plink/>) to evaluate the association between the SNPs and CAD.

Statistical analyses were performed using Microsoft Excel and PLINK software. And two-sided *p*-values \< 0.05 were considered statistically significant.
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